Member Info for Bobbler

Aber, I’m sure news will come in due course. The BOD are having a meeting today around the camp fire at their new HQ. The communication issue is due the Wi-Fi not operating very well inside the tents that are the new offices. But on the bright side this keeps the overheads down and they don’t need to worry about keeping the lights on as there aren’t any. All is Rosie.

I’m guessing you would know the answer to your own question.

What a Pea nus.

Can you imagine what it must feel like as a person to know you make a living like this? I wonder if Robin goes to bed dreaming about those people he see’s who have friends and relationships. Because I doubt very much anyone would want to spend time with him. Sad really.

We were so lucky to have our own financial guru on board in the guise of Dr Parker. Just imagine how bad a deal we might have entered into without his advice and experience to guide us.

If Fred were only entitled to a fixed number of shares, he would have NO incentive or desire to see the stock price decline. In our previous example, Fred and his group has a moving target on the number of total shares, incentivizing the “investors” into manipulating the stock downward. Even if the price of the stock dips, the investors still make their money back. Here’s the real catch: the investors now short the stock, covering their short positions with their convertible debenture at any time, regardless of the price of the stock. This is especially egregious and easy to do with microcap stocks where the stock is thinly-traded with little to no public float. The “investors” can more easily significantly drive the price downward by selling short.

In a famous case in 2003, Thomas Newkirk, then the Associate Director of the SEC’s Division of Enforcement, stated the following in relation to toxicity of “death spiral” finance:

Certain convertible securities, particularly those referred to as ‘toxic’ or ‘death spiral’ convertibles, present the temptation for persons holding the convertible securities to engage in manipulative short selling of the issuer's stock in order to receive more shares at the time of conversion.

Manipulators of this type rarely get away with such a scheme without collusive, stupid or desperate company owners. Legitimate, institutional investors don’t typically come calling until the share price reaches at least the $4 level. Even then, one must be cautious and perform relevant due diligence on the terms of an convertible debenture. Even desperate company managers who knowingly allow such shorts to happen run the risk of later unwanted action by regulators. In all, it’s best not to even contemplate playing in the mud, otherwise you’re liable to get very dirty. In other words, work on building a great company, instead of using fanciful financial engineering to attempt to make a quick buck.

Not sure there is any appetite any more. The SP is in free fall, it’s a shambles.

Superrich. Er how does that happen then? The share price is based on the last trade. You can’t have a trade price of zero.

On the bright side, despite what the likes of Robin say the share price can’t go to zero.

Https://opuscf.com/people/dr-stephen-b-parker/

Really !

Good question. Arranging to borrow £5m has cost over£50 million. Parker is clearly a waste of rations, its starting to look very unpleasant.

Dr Tim Mitchell, CEO of Sareum, commented:

"With a newly agreed funding facility designed to support Sareum through the Phase 1 study of its lead programme, SDC-1801, and good initial progress on the Phase 1a part of the trial, Sareum has begun the new financial year with significant momentum.………………

Tim I think it’s time to explain what’s happening ref momentum.

Know the feeling Humdinger £400k to Fook all.

Greed. Thought it would return £1m, my missus love’s to remind me how many times she told me to sell 🤔

Looking good for a blue finish……

Probably as likely as buy out above £50m

Must say I’m surprised at the level of buying. Either there’s someone out there who knows something we don’t or there’s a never ending supply of punters as daft as us 😀

Considering where the SP is currently and most likely to head, the LTH’s would be better chipping in and buying the company. Probably be worth less than 3m soon!

The board have clearly lost the plot.

As the licencee is a Private company, is it correct to say they can’t do a conventional raise. Therefore are we looking at a company that will raise funds via a biotech crowdfunding platform? If so it might not be so difficult to identify them.

I was surprised to read on the Advfn board

That Stephen Parker is part of OPUS Corporate Finance, which is correct. Considering what Opus do, (capital raising) RF seems a bizarre choice.

https://opuscf.com/people/dr-stephen-b-parker/

As we used to say in the good old days……

“Wouldn’t want to be out of this over the weekend”

Never mind it’s the weekend and we’ve got Monday to look forward to…. Can’t wait for the share holder value to kick in 😂😂😂

Wow. What a shambles this has turned into. Despite the clinical advances it’s looking like it’s going down and down. If they run out of cash they’ll be snapped up for next to nothing, Sirius Minerals springs to mind.

Hi HBD,

2023-11-17.Application filed by シエラ オンコロジー エルエルシー

Application filed by: That translate to Sierra Oncology, surprised they are filing a patent in November last year??!